PMID- 26731039
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20230124
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 16
IP  - 4
DP  - 2016 Apr
TI  - Long-Term Outcomes of Living-Donor Liver Transplantation for Primary Biliary 
      Cirrhosis: A Japanese Multicenter Study.
PG  - 1248-57
LID - 10.1111/ajt.13583 [doi]
AB  - The factors that influence long-term outcomes after living-donor liver 
      transplantation (LDLT) for primary biliary cirrhosis (PBC) are not well known. 
      Compared with deceased-donor transplantation, LDLT has an increased likelihood of 
      a related donor and a decreased number of human leukocyte antigen (HLA) 
      mismatches. To clarify the effects of donor relatedness and HLA mismatch on the 
      outcomes after LDLT, we retrospectively analyzed 444 Japanese patients. Donors 
      were blood relatives for 332 patients, spouses for 105, and "other" for 7. The 
      number of HLA A-B-DR mismatches was none to two in 141, three in 123, and four to 
      six in 106 patients. The 15-year survival rate was 52.6%, and PBC recurred in 65 
      patients. Recipient aged 61 years or older, HLA mismatches of four or more 
      (maximum of six), graft:recipient weight ratio less than 0.8, and husband donor 
      were adverse indicators of patient survival. IgM 554 mg/dL or greater, 
      donor-recipient sex mismatch, and initial immunosuppression with cyclosporine 
      were significant risks for PBC recurrence, which did not affect patient survival. 
      In subgroup analysis, conversion to cyclosporine from tacrolimus within 1 year 
      diminished recurrence. Prospective studies are needed to determine the influence 
      of pregnancy-associated sensitization and to establish an optimal 
      immunosuppressive regimen in LDLT patients.
CI  - (c) Copyright 2015 The American Society of Transplantation and the American Society 
      of Transplant Surgeons.
FAU - Egawa, H
AU  - Egawa H
AD  - Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical 
      University, Tokyo, Japan.
FAU - Sakisaka, S
AU  - Sakisaka S
AD  - Department of Gastroenterology, Fukuoka University, Fukuoka, Japan.
FAU - Teramukai, S
AU  - Teramukai S
AD  - Department of Biostatistics, Kyoto Prefectural University of Medicine Graduate 
      School of Medical Science, Kyoto, Japan.
FAU - Sakabayashi, S
AU  - Sakabayashi S
AD  - Department of Biostatistics, Kyoto Prefectural University of Medicine Graduate 
      School of Medical Science, Kyoto, Japan.
FAU - Yamamoto, M
AU  - Yamamoto M
AD  - Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical 
      University, Tokyo, Japan.
FAU - Umeshita, K
AU  - Umeshita K
AD  - Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, 
      Japan.
FAU - Uemoto, S
AU  - Uemoto S
AD  - Department of Surgery, Graduate School of Medicine, Kyoto University.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20160105
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of 
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Rejection/etiology/*prevention & control
MH  - Graft Survival
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Japan
MH  - Liver Cirrhosis, Biliary/*surgery
MH  - *Liver Transplantation
MH  - *Living Donors
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - clinical research, practice
OT  - hepatology
OT  - immune modulation, liver transplantation
OT  - immunosuppression
OT  - liver transplantation
OT  - living donor, immunosuppressant, calcineurin inhibitor (CNI)
OT  - recurrent disease, sensitization, alloantibody
EDAT- 2016/01/06 06:00
MHDA- 2017/01/18 06:00
CRDT- 2016/01/06 06:00
PHST- 2015/04/29 00:00 [received]
PHST- 2015/09/29 00:00 [revised]
PHST- 2015/10/12 00:00 [accepted]
PHST- 2016/01/06 06:00 [entrez]
PHST- 2016/01/06 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
AID - S1600-6135(22)00889-9 [pii]
AID - 10.1111/ajt.13583 [doi]
PST - ppublish
SO  - Am J Transplant. 2016 Apr;16(4):1248-57. doi: 10.1111/ajt.13583. Epub 2016 Jan 5.